Impact of NCI Socioeconomic Index on the Outcomes of Nonmetastatic Breast Cancer Patients: Analysis of SEER Census Tract-Level Socioeconomic Database.

Abstract:

PURPOSE:To assess the impact of National Cancer Institute socioeconomic status (SES) index on breast cancer-specific survival (BCSS) of nonmetastatic breast cancer patients registered within the Surveillance, Epidemiology and End Results (SEER) census tract-level SES database. PATIENTS AND METHODS:The census tract-level SES index is a composite score integrating 7 parameters that assess different dimensions of SES. Women with a nonmetastatic breast cancer diagnosis (stage I-III) diagnosed during 2010-2015 and included in the SEER-SES specialized database were included in the current analysis. Multivariate Cox regression analysis was used to assess the impact of SES index on BCSS. RESULTS:A total of 296,100 women with nonmetastatic breast cancer were included in the current study. The impact of SES index on BCSS was evaluated in the overall cohort of patients through multivariate Cox regression analysis (adjusted for age at diagnosis, race, stage, and breast cancer subtype). Lower SES was associated with worse BCSS (hazard ratio for group 1 [lowest SES group] vs. group 3 [highest SES group]: 1.428; 95% confidence interval, 1.359-1.499; P < .001). Using additional interaction testing within Cox regression models, the impact of SES on BCSS seems to be modified by breast cancer subtype (P for interaction < .001), race (P for interaction = .001), and stage (P for interaction = .015). CONCLUSION:Lower SES index is associated with worse BCSS. Further efforts need to be directed to improving breast cancer outcomes among women with socioeconomically vulnerable attributes (poverty, lower education, and unemployment).

journal_name

Clin Breast Cancer

journal_title

Clinical breast cancer

authors

Abdel-Rahman O

doi

10.1016/j.clbc.2019.06.013

subject

Has Abstract

pub_date

2019-12-01 00:00:00

pages

e717-e722

issue

6

eissn

1526-8209

issn

1938-0666

pii

S1526-8209(19)30647-0

journal_volume

19

pub_type

杂志文章
  • Rationale and clinical trial design for evaluating gemcitabine as neoadjuvant and adjuvant therapy for breast cancer.

    abstract::Over the past 30 years, much progress has been made in adjuvant chemotherapy for patients with early-stage breast cancer. The introduction of anthracyclines and, recently, taxanes has significantly improved the efficacy of adjuvant chemotherapy and has provided useful insight regarding future development of even more ...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章,评审

    doi:10.3816/cbc.2004.s.006

    authors: Mamounas EP,Geyer CE Jr,Swain SM

    更新日期:2004-01-01 00:00:00

  • JAK2 and PD-L1 Amplification Enhance the Dynamic Expression of PD-L1 in Triple-negative Breast Cancer.

    abstract:BACKGROUND:Activation of the JAK/STAT pathway is common in triple-negative breast cancer (TNBC) and affects the expression of genes controlling immune signaling. A subset of TNBC cases will have somatic amplification of chromosome 9p24.1, encoding PD-L1, PD-L2, and JAK2, which has been associated with decreased surviva...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章

    doi:10.1016/j.clbc.2018.05.006

    authors: Chen M,Pockaj B,Andreozzi M,Barrett MT,Krishna S,Eaton S,Niu R,Anderson KS

    更新日期:2018-10-01 00:00:00

  • Comparative acute toxicity from whole breast irradiation using 3-week accelerated schedule with concomitant boost and the 6.5-week conventional schedule with sequential boost for early-stage breast cancer.

    abstract:BACKGROUND:We aimed to evaluate the incidence of acute toxicity in a 3-week accelerated radiation therapy (RT) schedule with a concomitant boost compared with the 6.5-week conventional schedule with a sequential boost for early-stage, node-negative breast cancer. MATERIALS AND METHODS:This study included the first 50 ...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章,随机对照试验

    doi:10.1016/j.clbc.2011.09.002

    authors: Chadha M,Vongtama D,Friedmann P,Parris C,Boolbol SK,Woode R,Harrison LB

    更新日期:2012-02-01 00:00:00

  • Therapeutic efficacy of a novel nanosomal docetaxel lipid suspension compared with taxotere in locally advanced or metastatic breast cancer patients.

    abstract:BACKGROUND:Nanosomal docetaxel lipid suspension formulation was developed to eliminate ethanol and polysorbate 80 from the currently used docetaxel (Taxotere) drug for treatment of cancer patients. NDLS clinical safety and efficacy was evaluated and compared with Taxotere at 75 mg/m(2) in metastatic breast cancer patie...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章,随机对照试验

    doi:10.1016/j.clbc.2013.09.011

    authors: Ahmad A,Sheikh S,Taran R,Srivastav SP,Prasad K,Rajappa SJ,Kumar V,Gopichand M,Paithankar M,Sharma M,Rane RC,Ahmad I

    更新日期:2014-06-01 00:00:00

  • Comparison of HER2 detection methods between central and regional laboratories in Greece.

    abstract:PURPOSE:HER2 gene amplification and overexpression is associated with aggressive breast cancer and poor prognosis. Accurate HER2 testing of patients with breast cancer before treatment is important to ensure that as many patients with HER2-positive breast cancer as possible receive the most appropriate treatment and th...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章

    doi:10.3816/CBC.2007.n.040

    authors: Papadopoulos S,Kouvatseas G,Skarlos D,Malamos N,Delliou E,Saratsiotou I,Ardavanis A,Mavroudis D,Skarpidi E,Arapantoni P,Karyda I,Patakioyta F,Aravantinos G,Razis E,Fountzilas G,Kosmidis P

    更新日期:2007-10-01 00:00:00

  • Intermittent Letrozole Administration as Adjuvant Endocrine Therapy for Postmenopausal Women With Hormone Receptor-Positive Early Breast Cancer: A Biologic Study.

    abstract:BACKGROUND:Letrozole withdrawal for 3 months might permit estrogenic stimulation in residual resistant breast cancer disease susceptible to letrozole reintroduction. We investigated the impact of a 3-month letrozole-free interval on serum estradiol levels in patients with early stage breast cancer. PATIENTS AND METHOD...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章

    doi:10.1016/j.clbc.2015.03.007

    authors: Balduzzi A,Bagnardi V,Sandri MT,Dellapasqua S,Cardillo A,Montagna E,Cancello G,Iorfida M,Ghisini R,Viale G,Intra M,Luini A,Goldhirsch A,Colleoni M

    更新日期:2015-10-01 00:00:00

  • Predictive Biomarker Profiling of > 6000 Breast Cancer Patients Shows Heterogeneity in TNBC, With Treatment Implications.

    abstract:BACKGROUND:Triple-negative breast cancer (TNBC) is an aggressive disease without established targeted treatment options for patients with metastatic disease. This study was undertaken to evaluate potentially actionable biomarkers in a large cohort of TNBC and compare them with non-TNBCs. MATERIALS AND METHODS:We evalu...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章

    doi:10.1016/j.clbc.2015.04.008

    authors: Millis SZ,Gatalica Z,Winkler J,Vranic S,Kimbrough J,Reddy S,O'Shaughnessy JA

    更新日期:2015-12-01 00:00:00

  • BMI and Pathologic Complete Response to Neoadjuvant Chemotherapy in Breast Cancer: A Study and Meta-Analysis.

    abstract:INTRODUCTION:There is only limited data from clinical practice on the relevance of body mass index (BMI) on pathologic complete response (pCR) following neoadjuvant chemotherapy (NAC) in patients with breast cancer (BC). PATIENTS AND METHODS:The impact of BMI on pCR and survival outcome was examined in 324 patients wi...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章,meta分析

    doi:10.1016/j.clbc.2016.02.018

    authors: Erbes T,Stickeler E,Rücker G,Buroh S,Asberger J,Dany N,Thornton S,Iborra S,Hirschfeld M,Gitsch G,Mayer S

    更新日期:2016-08-01 00:00:00

  • Incidence of invasive breast cancer in postmenopausal women after discontinuation of long-term raloxifene administration.

    abstract:BACKGROUND:Postmenopausal women with osteoporosis had a 66% relative risk reduction for invasive breast cancer over 8 years of raloxifene therapy in the randomized, placebo-controlled 4-year MORE (Multiple Outcomes of Raloxifene Evaluation) trial and the CORE (Continuing Outcomes Relevant to Evista) trial, a 4-year fol...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.3816/CBC.2009.n.008

    authors: Vogel VG,Qu Y,Wong M,Mitchell B,Mershon JL

    更新日期:2009-02-01 00:00:00

  • Five-Year Oncologic Outcomes of Volume Displacement Procedures After Partial Mastectomy for Breast Cancer.

    abstract:BACKGROUND:Volume displacement techniques that use remnant breast tissue are useful in reconstructive procedures after partial mastectomy. The authors analyzed the oncologic results of volume displacement surgery after partial mastectomy and their associations with various clinicopathologic factors. PATIENTS AND METHO...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章

    doi:10.1016/j.clbc.2016.06.018

    authors: Lee J,Jung JH,Kim WW,Hwang SO,Chae YS,Lee SJ,Yang JD,Lee JW,Park HY

    更新日期:2017-02-01 00:00:00

  • A phase II trial of neoadjuvant gemcitabine, epirubicin, and docetaxel as primary treatment of patients with locally advanced or inflammatory breast cancer.

    abstract:BACKGROUND:Three-drug regimens containing gemcitabine, an anthracycline, and a taxane produce response rates of 70%-90% in patients with metastatic breast cancer (MBC) although accompanied by considerable hematologic toxicity. We explored the combination of gemcitabine/epirubicin/docetaxel as neoadjuvant therapy. Docet...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章,多中心研究

    doi:10.3816/CBC.2010.n.029

    authors: Yardley DA,Peacock NW,Dickson NR,White MB,Vázquez ER,Foust JT,Grapski R,Hendricks LK,Scott WL,Hainsworth JD

    更新日期:2010-06-01 00:00:00

  • Basal Protein Expression Is Associated With Worse Outcome and Trastuzamab Resistance in HER2+ Invasive Breast Cancer.

    abstract:BACKGROUND:We investigated the effect of basal protein expression on trastuzamab response in patients with HER2-positive (HER2(+)) breast cancer who received trastuzamab (T) and in HER2(+) breast cancer cell lines. PATIENTS AND METHODS:Expression of cytokeratin (CK) 5/6, CK14, and epidermal growth factor receptor (EGF...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章

    doi:10.1016/j.clbc.2015.06.001

    authors: Chung A,Choi M,Han BC,Bose S,Zhang X,Medina-Kauwe L,Sims J,Murali R,Taguiam M,Varda M,Schiff R,Giuliano A,Cui X

    更新日期:2015-12-01 00:00:00

  • The effect of aromatase inhibition on the cognitive function of older patients with breast cancer.

    abstract:INTRODUCTION:This study evaluated the association between aromatase inhibitor (AI) therapy and cognitive function (over a 6-month period) in a cohort of patients aged ≥ 60 years compared with an age-matched healthy control group, and it evaluated changes in regional cerebral metabolism as measured by positron emission ...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章

    doi:10.1016/j.clbc.2013.10.010

    authors: Hurria A,Patel SK,Mortimer J,Luu T,Somlo G,Katheria V,Ramani R,Hansen K,Feng T,Chuang C,Geist CL,Silverman DH

    更新日期:2014-04-01 00:00:00

  • Neoadjuvant trastuzumab and docetaxel in breast cancer: preliminary results.

    abstract::Trastuzumab/chemotherapy combinations have already shown superior results in metastatic breast cancer patients. The purpose of this study is to determine the clinical efficacy of neoadjuvant trastuzumab and docetaxel in women with locally advanced breast cancer, with or without metastatic disease. Treatment-naive wome...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章

    doi:10.3816/cbc.2003.n.040

    authors: Van Pelt AE,Mohsin S,Elledge RM,Hilsenbeck SG,Gutierrez MC,Lucci A Jr,Kalidas M,Granchi T,Scott BG,Allred DC,Chang JC

    更新日期:2003-12-01 00:00:00

  • The Accuracy of Breast MR Imaging for Measuring the Size of a Breast Cancer: Analysis of the Histopathologic Factors.

    abstract:BACKGROUND:The objective of the study was to compare the accuracy of different magnetic resonance (MR) sequences for measuring tumor size and to evaluate whether the imaging and histopathologic features affect the accuracy of the tumor size estimation on the MR sequence. PATIENTS AND METHODS:Eight hundred women were i...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章

    doi:10.1016/j.clbc.2016.07.007

    authors: Choi WJ,Cha JH,Kim HH,Shin HJ,Chae EY

    更新日期:2016-12-01 00:00:00

  • Race as an independent risk factor for breast cancer survival: breast cancer outcomes from the medical college of georgia tumor registry.

    abstract:BACKGROUND:Causes of racial disparities in breast cancer survival remain unclear. This study assesses overall survival (OS) after diagnosis between black and white women and examines factors that might correlate with this disparity. PATIENTS AND METHODS:Data were obtained from the Medical College of Georgia Tumor Regi...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章

    doi:10.3816/CBC.2010.n.008

    authors: Barcenas CH,Wells J,Chong D,French J,Looney SW,Samuel TA

    更新日期:2010-02-01 00:00:00

  • Breast Reconstruction Actualized in Nipple-sparing Mastectomy and Direct-to-implant, Prepectoral Polyurethane Positioning: Early Experience and Preliminary Results.

    abstract:BACKGROUND:Implant-based breast reconstruction after nipple-sparing mastectomy has been the most common breast reconstruction procedure performed, for both breast cancer treatment and prophylactically. Subpectoral implant placement with partial detachment of the pectoralis major muscle has been the procedure of choice ...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章

    doi:10.1016/j.clbc.2018.12.015

    authors: de Vita R,Buccheri EM,Villanucci A,Pozzi M

    更新日期:2019-04-01 00:00:00

  • Downregulation of the cyclin-dependent kinase inhibitor p27kip1 might correlate with poor disease-free and overall survival in inflammatory breast cancer.

    abstract:PURPOSE:The objective of this study was to evaluate whether p27kip1 downregulation is a prognostic factor in patients with inflammatory breast carcinoma (IBC). PATIENTS AND METHODS:Fifty-eight patients with IBC were treated between January 1994 and July 2002. Median age was 49 years. Thirty-eight patients had baseline...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章

    doi:10.3816/CBC.2006.n.045

    authors: Gonzalez-Angulo AM,Guarneri V,Gong Y,Cristofanilli M,Morales-Vasquez F,Sneige N,Hortobagyi GN,Esteva FJ

    更新日期:2006-10-01 00:00:00

  • Phase II trial of gemcitabine plus trastuzumab in metastatic breast cancer patients previously treated with chemotherapy: preliminary results.

    abstract::Preliminary results of a phase II study of gemcitabine plus trastuzumab in previously treated (up to 3 previous regimens) metastatic breast cancer patients are presented. Patients had histologically confirmed metastatic breast cancer, with 2+ or 3+ tumor HER2 expression. Treatment consisted of gemcitabine 1200 mg/m2 o...

    journal_title:Clinical breast cancer

    pub_type: 临床试验,杂志文章

    doi:10.3816/cbc.2002.s.004

    authors: O'Shaughnessy J,Vukelja SJ,Marsland T,Kimmel G,Ratnam S,Pippen J

    更新日期:2002-05-01 00:00:00

  • Classification, Treatment Strategy, and Associated Drug Resistance in Breast Cancer.

    abstract::Breast cancer is the second leading cause of cancer death in women, affecting 1.7 million patients every year worldwide. As a result of its heterogeneous nature, the genetic profile and associated clinical feature varies greatly among different breast cancer subtypes. With the advancement of molecular biology, our und...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章,评审

    doi:10.1016/j.clbc.2016.05.012

    authors: Tang Y,Wang Y,Kiani MF,Wang B

    更新日期:2016-10-01 00:00:00

  • Predicting Brain Metastasis in Breast Cancer Patients: Stage Versus Biology.

    abstract:BACKGROUND:Brain metastasis (BM) is a life-threatening event in breast cancer patients. Identifying patients at a high risk for BM can help to adopt screening programs and test preventive interventions. We tried to identify the incidence of BM in different stages and subtypes of breast cancer. PATIENTS AND METHODS:We ...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章

    doi:10.1016/j.clbc.2017.08.004

    authors: Azim HA,Abdel-Malek R,Kassem L

    更新日期:2018-04-01 00:00:00

  • Magnetic resonance imaging-guided core needle breast biopsies resulting in high-risk histopathologic findings: upstage frequency and lesion characteristics.

    abstract:UNLABELLED:Analysis of magnetic resonance imaging-guided breast biopsies yielding high-risk histopathologic features at a single institution found an overall upstage rate to malignancy of 14% at surgical excision. All upstaged lesions were associated with atypical ductal hyperplasia. Flat epithelial atypia and atypical...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章

    doi:10.1016/j.clbc.2014.12.005

    authors: Weinfurtner RJ,Patel B,Laronga C,Lee MC,Falcon SL,Mooney BP,Yue B,Drukteinis JS

    更新日期:2015-06-01 00:00:00

  • Effects of DNA ploidy and S-phase fraction on fluorine-18 FDG uptake of primary breast cancer lesions.

    abstract:BACKGROUND:Flow cytometry (FCM) evaluating DNA content is emerging as the tool to monitor cell proliferation and malignant potential in several cancers such as stomach, lung, and salivary gland tumor. The purpose of this study was to correlate (18)F-FDG uptake of dual-time-point (DTP) positron emission tomography (PET)...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章

    doi:10.1016/j.clbc.2012.09.010

    authors: Kim DW,Kim CG

    更新日期:2013-06-01 00:00:00

  • A Reappraisal of the Comparative Effectiveness of Lumpectomy Versus Mastectomy on Breast Cancer Survival: A Propensity Score-Matched Update From the National Cancer Data Base (NCDB).

    abstract:BACKGROUND:Recent observational studies are concerning because they document rising mastectomy rates coinciding with more than a dozen reports that lumpectomy has better overall survival (OS) than mastectomy. Our aim was to determine if there were differences in OS of matched breast cancer patients undergoing lumpectom...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章

    doi:10.1016/j.clbc.2019.02.006

    authors: Landercasper J,Ramirez LD,Borgert AJ,Ahmad HF,Parsons BM,Dietrich LL,Linebarger JH

    更新日期:2019-06-01 00:00:00

  • Does the result of completion axillary lymph node dissection influence the recommendation for adjuvant treatment in sentinel lymph node-positive patients?

    abstract:OBJECTIVE:The Hungarian National Institute of Oncology has just closed a single-center randomized clinical study. The Optimal Treatment of the Axilla-Surgery or Radiotherapy (OTOASOR) trial compares completion axillary lymph node dissection (cALND) with regional nodal irradiation (RNI) in patients with sentinel lymph n...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章,随机对照试验

    doi:10.1016/j.clbc.2013.04.004

    authors: Sávolt A,Polgár C,Musonda P,Mátrai Z,Rényi-Vámos F,Tóth L,Kásler M,Péley G

    更新日期:2013-10-01 00:00:00

  • Novel approaches to postoperative radiation therapy as part of breast-conserving therapy for early-stage breast cancer.

    abstract::Breast-conserving therapy (BCT) consists of segmental mastectomy followed by postoperative radiation therapy (RT) to the whole breast. At least 6 prospective randomized trials have proven the equivalence of BCT to mastectomy. However, BCT remains underused and, most importantly, a sizable proportion of patients with i...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章,评审

    doi:10.3816/cbc.2003.n.030

    authors: Truong MT,Hirsch AE,Formenti SC

    更新日期:2003-10-01 00:00:00

  • A Survey of Breast Pathologists' Practice in Staging Multiple Foci of Invasive Carcinoma.

    abstract:BACKGROUND:The American Joint Committee on Cancer (AJCC) staging system is the reference standard for describing the extent of neoplastic disease on the basis of the size of primary tumor (T), and the presence of regional lymph node (N) involvement and distant metastasis (M). Multiple foci of invasive breast carcinoma ...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章

    doi:10.1016/j.clbc.2020.11.018

    authors: Wu JM,Turashvili G

    更新日期:2020-12-05 00:00:00

  • A Guide to Prepectoral Breast Reconstruction: A New Dimension to Implant-based Breast Reconstruction.

    abstract::Acellular dermal matrix has revolutionized implant-based breast reconstruction. Breast reconstruction has evolved from the traditional submuscular to the new prepectoral implant based (also known as muscle-sparing) reconstruction. The new technique is emerging as a highly popular surgery owing to its more minimal appr...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章,评审

    doi:10.1016/j.clbc.2016.11.009

    authors: Vidya R,Iqbal FM

    更新日期:2017-07-01 00:00:00

  • CDK4/6 Inhibitors in Combination With Hormone Therapy for HR+/HER2- Advanced Breast Cancer: A Systematic Review and Meta-analysis of Randomized Controlled Trials.

    abstract:BACKGROUND:This meta-analysis of randomized controlled trials aimed to comprehensively assess the efficacy and toxicity of cyclin-dependent kinase (CDK) 4/6 inhibitors in advanced breast cancer (ABC) with hormone-receptor positive (HR+) and human epidermal growth factor receptor 2 negative (HER2-) disease. METHODS:We ...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章,meta分析

    doi:10.1016/j.clbc.2018.04.017

    authors: Deng Y,Ma G,Li W,Wang T,Zhao Y,Wu Q

    更新日期:2018-10-01 00:00:00

  • Neoadjuvant endocrine therapy in primary breast cancer.

    abstract::Neoadjuvant chemotherapy has been employed increasingly in operable breast cancer during recent years. Several randomized trials showed that the chances of breast conserving therapy are being enhanced, and that survival was not compromised by primary systemic therapy compared to adjuvant treatment. Apart from the surg...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章,评审

    doi:10.3816/cbc.2004.n.039

    authors: Huober J,Krainick-Strobel U,Kurek R,Wallwiener D

    更新日期:2004-12-01 00:00:00